ARTICLE | Company News
Neurogen, Aventis deal
January 5, 2004 8:00 AM UTC
NRGN received a $1 million milestone from AVE under the companies' 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1). The payment was triggered by a preclinical milesto...